Ranibizumab in the ARMD Wet Form Treatment – Two Years Results Obtained from the AMADEuS Registry
Authors:
V. Matušková 1; P. Kolář 1; D. Vysloužilová 1; E. Vlková 1; L. Dušek 2; V. Kandrnal 2; J. Jarkovský 2; M. Uher 2
Authors‘ workplace:
Oční klinika LF MU a FN Brno, přednostka prof. MUDr. Eva Vlková, CSc.
1; Institut biostatistiky a analýz, MU Brno
ředitel doc. RNDr. Ladislav Dušek, Ph. D
2
Published in:
Čes. a slov. Oftal., 68, 2012, No. 5, p. 171-177
Category:
Original Article
Overview
Aim:
The aim of this study was the retrospective follow up of Age-Related Macular Degeneration (ARMD) wet form patients treated with ranibizumab during 24 months period. The data were recorded into the AMADEuS (Age-related MAcular DEgeneration in patientS in the Czech Republic) Registry and after their evaluation compared with treatment results obtained from other departments of ophthalmology collaborating in the AMADEuS project or results of some foreign studies as well.
Patients and methods:
The group consisted of patients registered since October 1, 2008 until June 11, 2012, followed up for 24 months period. There were 90 eyes of 89 patients. All patients were completely examined in the Macular ambulance of the Department of Ophthalmology in the Faculty Hospital Brno-Bohunice, Czech Republic, E.U., and consequently the ranibizumab (Lucentis, Novartis) was applied intravitreally in three initials doses one month apart. Thereafter, ranibizumab was applied “on demand”. In 43.3 % of eyes the mostly classical, in 27.8 % of eyes occult, and in 28.9 % of eyes the minimally classical choroid neovascular membrane was present. The initial visual acuity was in 3.3 % of eyes in the range 15 – 30 letters of ETDRS optotypes (20/500 – 20/200), in 61.1 % of eyes in the range 31 – 60 letters (20/200 – 20/63), and the visual acuity better than 61 letters of ETDRS optotypes (better than 20/63) was in 35.6 % of eyes.
Results:
The average initial best-corrected visual acuity (BCVA) in our group of patients was 54.2 letters of EDTRS (SD ± 14.4). At the visit at three months after the start of the treatment the BCVA was 59.6 letters of EDTRS (SD ± 15.0), at the visit after 6 months 57.3 letters of EDTRS (SD ± 14.7), after one year of the study 54.8 letters of EDTRS (SD ± 16), after 18 months of the study 53.4 letters of EDTRS (SD ± 16,8), and after 24 months of the study was the BCVA 51.7 letters of EDTRS (SD ± 16.9). The average CRT (central retinal thickness) value by means of the OCT (optic coherence tomography) examination was at the beginning of the treatment 311.4 μm (SD ± 117.9), after 3 months of treatment 233.5 μm, (SD ± 85.4), after 6 months of treatment 262.2 μm, (SD ± 102,4), after 12 months 261 μm (SD ± 88,4), after 18 months 254.9 μm (SD ± 70.0), and after 24 months 249 μm (SD ± 87.5). The average number of ranibizumab doses during the follow-up period was 5.6. After the 24 months follow-up period, the gain of 15 or more letters of EDTRS was recorded in 11.1 % of patients, the gain of 1 – 14 letters of EDTRS optotypes was recorded in 32.2 % of patients, the decrease of 14 or less letters of EDTRS optotypes was found in 21.2 % of patients, and the decrease of 15 or more letters was found in our group in 22.2 % of patients.
Conclusion:
The ARMD wet form treatment using ranibizumab is up to date the most effective available therapy. The AMADEuS registry is of great importance in the reviewing of the effectiveness of the ARMD wet form treatment.
Klíčová slova:
VPMD, registr, Amadeus, ranibizumab, vlhká forma, léčba
Sources
1. Abraham, P., Yue, H., Wilson, L.: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration, PIER study year 2, Am J Ophthalmol, 150, 2010; 3: 315–324.
2. Blick, S., Keating, G., Wagstaff, A.: Ranibizumab, Adis Drug Profile, 67, 2007; 8: 1199–1206.
3. Boguszaková , J., Sklivec a sítnice In Kuchynka P.: Oční lékařství, Praha, Grada, 2007, Praha, s 316–324.
4. Brown, D. M., Michels, M., Kaiser, P., K. et al.: for the ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study, Ophthalmology, 116, 2009, 1: 57–65.
5. Dušek, L., Pitrová, Š., Řehák, J. et al.: Informační zázemí České oftalmologické společnosti ČLS JEP pro monitoring a hodnocení léčby vlhké formy věkem podmíněné makulární degenerace - národní projekt AMADEUS. Čes a Slov Oftalmol, 66, 2010, 3: 99–109.
6. Ernest, J., Fišer, I., Kolář, P.: Věkem podmíněná makulární degenerace. Praha, Česká vitreoretinální společnost, 2007; 88 s.
7. Ferrara, N., Damico,L., Shams, N. et al.: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration, Retina, 26, 2006; 8: 859–870.
8. http://amadeus.registry.cz.
9. http://amadeus.registry.cz/index. php?pg=vysledky-a-publikace-analyticka-zprava-cerven-2012.
10. Chen, Y., Wiesmann, Ch., Germaine, F. et al.: Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fabin Complex with Antigen, J Mol Biol, 1999; 293, 865 –881.
11. Kolář, P.: Klasifikace a klinický obraz VPMD In Kolář., P: Věkem podmíněná makulární degenerace, Praha, Grada, 2008, s 59–74.
12. Kolář, P., Vlková, E., Vižďová, D.: Fotodynamická terapie s preparátem Visudyne v léčbě vlhké formy věkem podmíněné makulární degenerace – dvouleté výsledky. Čas Lék čes, 145, 2006; 10: 795 – 800.
13. Kolář, P.: Epidemiologie věkem podmíněné makulární degenerace. Čes a Slov Oftalmol, 66, 2010; 3: 127–130.
14. Kolář, P.: Ranibizumab u pacientů s vlhkou formou věkem podmíněné makulární degenerace – studie SUSTAIN. Farmakoterapie, 2009; 6: 579–580.
15. Kolář, P.: Věkem podmíněná makulární degenerace, Čas Lék čes, 144, 2005; 8: 516–520.
16. Kolář, P.: Věkem podmíněná makulární degenerace, Oftalmochirurgie, 3, 2008; 2: 9–21.
17. Kolář, P.: Macugen v léčbě vlhké formy věkem podmíněné makulární degenerace, Oftalmochirurgie, 3, 2008; 2: 37–42.
18. Kolář, P.: Ranibizumab (Lucentis) – nový lék k léčbě vlhké formy věkem podmíněné makulární degenerace. Praktické lékárenství, 2008; 6: 271–274.
19. Kolář, P.: Ranibizumab. Farmakoterapie. 2007; 5: 431–434.
20. Krohne, T. U., Liu, Z., Holz, F. G., Meyer, C.: Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans. Am J Ophthalmol, 2012; 154: 682–686.
21. Rosenfeld, P. J., Brown, D. M., Heier, J. S., et al.: for the MARINA Study Group: Ranibizumab for Neovascular Age-Related Macular Degeneration The New England Journal of Medicine, 355, 2006; 14: 1419–1431.
22. Sivaprasad, S., Hykin, P., Saeed, A. et al.: Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration, Pan-European experience. Eye, 5, 2010, 24: 793–798.
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2012 Issue 5
Most read in this issue
- The Application of Dysport® – the Possibilities of the Side Effect on the Eyelids Position (a Clinical – Histological study)
- Pars Plana Vitrectomy and Combination Therapy Pars Plana Vitrectomy, Intravitreal Triamcinolon Acetonid and Macular Lasercoagulation – One Year Results
- Clinical Variability of Best’s Disease
- Adjustable Versus Non-adjustable Sutures in Strabismus Surgery in Patients with Thyroid Ophthalmopathy